The advisory panel of the Food and Drug Administration, FDA recommends Moderna Covid-19 booster shot for older people as well as adults 18 years and above who are at high risk of contracting Covid-19 for medical and occupational reasons.
According to the panel, the booster shot should be given at least six months after the initial inoculation and is half the initial dose.
The safety data presented by Moderna to support their push for the booster dose was little. Moderna had presented data to the panel showing that its vaccine loses efficacy after some time therefore a booster shot is required to help restore levels of protective antibodies.
However, the FDA advisory panel decided that in the prevailing situation of the Covid-19 pandemic and with signs that some individuals at-risk could get some breakthrough, the Moderna booster shot was good enough to be used, and therefore recommends it.
The panel’s approval came after Moderna convinced them that the booster dose was safe as many individuals with weak immune systems had already taken a full third dose of the Moderna jab without any problems so far.
Earlier, the panel had also given similar approval to the use of Pfizer and BioNTechSE booster doses and this has since been cleared by the FDA for use in older and at-risk individuals.
The next stage will be for the FDA to either approve or disallow its use as the agency is not obligated to accept the panel’s recommendation.
After the FDA acts on it, it is sent to the Centre for Disease Control and Prevention’s (CDC) advisory panel which is expected to make its own recommendation to the Director of CDC, Rochelle Walensky. Walensky will then decide on what to do with it.
The FDA will on Friday consider booster shots from Johnson & Johnson.
At the end of this meeting, a discussion on matching and mixing boosters with different shots used in the initial immunization will hold.